We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-0.22%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$397M
AUM Growth
+$57.1M
Cap. Flow
+$74.2M
Cap. Flow %
18.68%
Top 10 Hldgs %
84.31%
Holding
27
New
4
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
RNAC icon
Cartesian Therapeutics
RNAC
+$16.5M
2
VRNA
Verona Pharma
VRNA
+$9.33M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$2.78M
4
TMBR
Timber Pharmaceuticals, Inc.
TMBR
+$749K
5
AIMT
Aimmune Therapeutics
AIMT
+$263K

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$4.7M
2
KALV
KalVista Pharmaceuticals
KALV
+$2.35M
3
DVAX
Dynavax Technologies
DVAX
+$6

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$739M
$77.5M 19.52%
2,858,569
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.3B
$49M 12.35%
1,766,832
– –
NBRV
3
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$42.1M 10.61%
16,086
– –
CDXS icon
4
Codexis
CDXS
$136M
$28.9M 7.27%
5,294,825
– –
RNAC icon
5
Cartesian Therapeutics
RNAC
$225M
$22.2M 5.6%
+37,306
New +$16.5M
SBBP
6
DELISTED
Strongbridge Biopharma plc.
SBBP
$21.4M 5.4%
3,000,000
– –
AIMT
7
DELISTED
Aimmune Therapeutics
AIMT
$16M 4.02%
776,813
+13,804
+2% +$263K
EIGR
8
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$14.1M 3.56%
59,570
– –
AAAP
9
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$14M 3.53%
358,786
-125,000
-26% -$4.7M
VRNA
10
DELISTED
Verona Pharma
VRNA
$8.21M 2.07%
+704,225
New +$9.33M
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$7.36M 1.85%
195,937
– –
TMBR
12
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$6.75M 1.7%
940
+86
+10% +$749K
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$1.92B
$6.21M 1.56%
1,013,149
+413,149
+69% +$2.78M
AGRX
14
DELISTED
Agile Therapeutics
AGRX
$5.68M 1.43%
757
– –
TRVN
15
DELISTED
Trevena, Inc.
TRVN
$3.97M 1%
2,765
– –
FOMX
16
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.97M 1%
855,000
– –
DVAX
17
DELISTED
Dynavax Technologies
DVAX
$3.47M 0.87%
359,827
-1
-0% -$6
RGNX icon
18
Regenxbio
RGNX
$606M
$3.25M 0.82%
164,403
– –
SRRA
19
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.85M 0.72%
60,957
– –
AKTX
20
Akari Therapeutics
AKTX
$14.4M
$2.43M 0.61%
660
– –
CRSP icon
21
CRISPR Therapeutics
CRSP
$4.64B
$2.38M 0.6%
148,878
– –
RVNC
22
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.04M 0.51%
77,373
– –
VIRX
23
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.35M 0.34%
14,286
– –
CAPNW
24
DELISTED
Capnia, Inc. Series A Warrant
CAPNW
$159K 0.04%
943,858
– –
KALV
25
DELISTED
KalVista Pharmaceuticals
KALV
– –
-300,325
Closed -$2.35M

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vivo Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Vivo Capital held 27 positions worth $397M, up 17% from $340M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Vivo Capital deployed $74.2M of net new capital in Q2 2017, opening 4 new positions and adding to 3 existing holdings. Its largest new stake was Cartesian Therapeutics: 37,306 shares worth $22.2M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Advanced Accelerator Applications S.A., an estimated $4.7M trimmed.

  • Vivo Capital's largest Q2 2017 buy was Cartesian Therapeutics: 37,306 shares worth $22.2M.
  • Vivo Capital added most to Aurinia Pharmaceuticals in Q2 2017, an estimated $2.78M increase.
  • Vivo Capital's biggest Q2 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $4.7M.
  • Vivo Capital fully exited KalVista Pharmaceuticals in Q2 2017, selling an estimated $2.35M.
  • Vivo Capital's ten largest holdings make up 84% of its $397M portfolio in Q2 2017.
  • Vivo Capital opened 4 new positions and closed 1 in Q2 2017.
  • Vivo Capital's portfolio value rose 17% quarter-over-quarter to $397M.

Based on Vivo Capital's 13F filing for Q2 2017, filed 2 Aug 2017.